SAN DIEGO, April 7, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by aTyr Pharma, Inc. (NASDAQ: LIFE) and certain of its officers. aTyr Pharma is a biotherapeutics company that engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases.
Specifically, Johnson & Weaver's investigation seeks to determine whether certain statements regarding aTyr Pharma's business and prospects were false and misleading when made.
On May 7, 2015, aTyr Pharma stock traded as high as $15.01, the day the Company sold 5.36 million shares of stock in its initial public stock offering (the "IPO"), raising $75 million in new capital. However, since the IPO, aTyr Pharma's stock has imploded, falling from its high of $28.29 in June 2015 to trade at $3.15 in early morning trading on April 7, 2016.
Specifically, Johnson & Weaver's investigation will seek to determine if certain of the Company's statements regarding its business and future prospects were false or misleading.
If you are an aTyr Pharma shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (email@example.com) at 619-814-4471. If you email, please include your phone number.
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atyr-pharma-life-alert-shareholder-rights-law-firm-johnson--weaver-llp-announces-investigation-of-atyr-pharma-inc-encourages-investors-to-contact-the-firm-for-additional-information-300247992.html
SOURCE Johnson & Weaver, LLP